Mink therapeutics and autonomous therapeutics announce collaboration to develop novel therapies targeting metastatic tumors

New york, oct. 08, 2024 (globe newswire) -- mink therapeutics (mink, nasdaq: inkt) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer t (inkt) cell therapies and autonomous therapeutics, inc. (autonomous), a leader developing first-in-class, disease-activated rna medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors.
INKT Ratings Summary
INKT Quant Ranking